Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Interventional Phase 3b Study to Evaluate the Safety, One-year Antibody Persistence, Priming Immune Responses of Three Doses of Eupolio Inj. (Inactivated Polio Vaccine (Sabin Strains)) and Immunogenicity of Two Doses of Eupolio Inj. Following Three Doses of bOPV in Infants

NCT05431933 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT05431933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05431933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Interventional Phase 3b Study to Evaluate the Safety, One-year Antibody Persistence, Priming Immune Responses of Three Doses of Eupolio Inj. (Inactivated Polio Vaccine (Sabin Strains)) and Immunogenicity of Two Doses of Eupolio Inj. Following Three Doses of bOPV in Infants
Lead sponsor
LG Chem
Phase
Phase 3
Overall status
Completed
Start date
January 10, 2023
Completion date
November 6, 2024
Enrollment
2,001 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis, vaccine reaction